Compare KTF & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTF | LYEL |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 320.1M |
| IPO Year | N/A | 2021 |
| Metric | KTF | LYEL |
|---|---|---|
| Price | $8.04 | $9.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | ★ 373.2K | 122.8K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.95 | $9.36 |
| 52 Week High | $9.37 | $45.00 |
| Indicator | KTF | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 25.77 | 23.04 |
| Support Level | N/A | N/A |
| Resistance Level | $9.26 | $15.38 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 13.21 | 10.46 |
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.